Copyright 1999 American Medical Association.
All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999
To the Editor: In
HERS,1 there was an increase in the risk of CHD events
associated with the use of HRT compared with placebo during the first
year of follow-up, but in subsequent years, the risk was lower in women
receiving HRT than placebo. In the accompanying Editorial, Dr
Petitti2 cites our findings for duration of HRT
use3 and suggests that these observational findings on
duration of use contradict the clinical trial findings on recency of
starting HRT. There are important differences between recency and
Heckbert SR, Weiss NS, Psaty BM. Hormone Replacement Therapy for Secondary Prevention of Coronary Heart Disease. JAMA. 1999;281(9):794–797. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-9-jbk0303
Customize your JAMA Network experience by selecting one or more topics from the list below.